Acceleron Ends ACE-083 FSHD Testing After Phase II Failure

 
• By Sten Stovall

Acceleron ended testing of ACE-083 in facioscapulohumeral muscular dystrophy after the investigational drug missed Phase II endpoints.

Muscular_Dystrophy
Acceleron Has Discontinued ACE-083 in facioscapulohumeral muscular dystrophy • Source: Shutterstock

More from Neurological

More from Therapy Areas